Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.
Fontana
Robert J
RJ
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA. rfontana@umich.edu
Everson
Gregory T
GT
Tuteja
Sony
S
Vargas
Hugo E
HE
Shiffman
Mitchell L
ML
D000998:Antiviral Agents / Q000008:administration & dosage*; D015897:Comorbidity; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D008103:Liver Cirrhosis / Q000453:epidemiology* / Q000473:pathology; D008297:Male; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage; D018570:Risk Assessment; D012720:Severity of Illness Index; D015996:Survival Rate; D016896:Treatment Outcome
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin